[Clinical evaluation of micronomicin for the treatment of postoperative infections in cancer patients].
Micronomicin (MCR, Sagamicin), a new derivative of aminoglycoside, was used in 9 patients with postoperative infection mainly caused by Gram-negative bacilli. A dose of 60-120 mg was intramuscularly administered continuously twice a day for 3-21 days. The therapeutic results were excellent in 2, good in 3, fair in 1 and poor in 2 cases. The assessment was impossible in 1 patient. The effective rate was 62.5%. No side effects were encountered in any cases.